EntryPoint Capital LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

EntryPoint Capital LLC lifted its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 52.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,760 shares of the company’s stock after acquiring an additional 18,127 shares during the quarter. EntryPoint Capital LLC’s holdings in Xeris Biopharma were worth $179,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Xeris Biopharma in the fourth quarter worth approximately $42,000. Quantbot Technologies LP bought a new position in Xeris Biopharma in the 3rd quarter worth $44,000. Cibc World Markets Corp purchased a new stake in Xeris Biopharma in the 4th quarter worth $44,000. Raymond James Financial Inc. bought a new stake in Xeris Biopharma during the fourth quarter valued at about $45,000. Finally, Virtu Financial LLC purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at about $58,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Down 0.9 %

Xeris Biopharma stock opened at $5.58 on Friday. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $6.07. The company has a market cap of $858.99 million, a price-to-earnings ratio of -12.40 and a beta of 2.32. The firm’s fifty day moving average is $4.13 and its 200 day moving average is $3.52.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on XERS shares. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.10.

Insider Activity

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.56% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.